Clinical Trials · NCT01086982

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Phase
Phase 1
Recruitment status
Suspended
Sponsor
Azidus Brasil
Enrollment
16
Start date
Mar 2010
Locations
1 site, Brazil
Primary endpoint
Quantification of serum levels of GH and IGF-I.
View Octreotide compound reference